Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters—a randomized, double‐blind, placebo‐controlled trial
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Objective: To evaluate the safety and efficacy of a novel formulation of midazolam administered as a single‐dose nasal spray ( MDZ – NS ) in the outpatient treatment of patients experiencing seizure clusters ( SC s). Methods: This was a phase III , randomized, double‐blind, placebo‐controlled trial (ClinicalTrials.gov NCT 01390220) with patients age ≥12 years on a stable regimen of antiepileptic drugs. Following an in‐clinic test dose phase ( TDP ), patients entered an outpatient comparative phase ( CP ) and were randomized (2:1) to receive double‐blind MDZ – NS 5 mg or placebo nasal spray, administered by caregivers when they experienced an SC . The primary efficacy end point was treatment success (seizure termination within 10 minutes and no recurrence 10 minutes to 6 hours after trial drug administration). Secondary efficacy end points were proportion of patients with seizure recurrence 10 minutes to 4 hours, and time‐to‐next seizure >10 minutes after double‐blind drug administration. Safety was monitored throughout. Results: Of 292 patients administered a test dose, 262 patients were randomized, and 201 received double‐blind treatment for an SC (n = 134 MDZ – NS , n = 67 placebo, modified intent‐to‐treat population). A significantly greater proportion of MDZ – NS ‐ than placebo‐treated patients achieved treatment success (53.7% vs 34.4%; P = 0.0109). Significantly, fewer MDZ – NS ‐ than placebo‐treated patients experienced seizure recurrence (38.1% vs 59.7%; P = 0.0043). Time‐to‐next seizure analysis showed early separation (within 30 minutes) between MDZ – NS and placebo that was maintained throughout the 24‐hour observation period (21% difference at 24 hours; P = 0.0124). Sixteen patients (5.5%) discontinued because of a treatment‐emergent adverse event ( TEAE ) during the TDP and none during the CP . During the CP , 27.6% and 22.4% of patients in the MDZ – NS and placebo groups, respectively, experienced ≥1 TEAE . Significance: MDZ – NS was superior to placebo in providing rapid, sustained seizure control when administered to patients experiencing an SC in the outpatient setting and was associated with a favorable safety profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lahat, E. (2000) · BMJ · doi:10.1136/bmj.321.7253.83 · Cited by 294
Benzodiazepines I: Upping the Care on Downers: The Evidence of Risks, Benefits and Alternatives
Guina, J., & Merrill, B. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7020017 · Cited by 253
Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children
Mahmoudian, T., & Mohammadi Zadeh, M. (2004) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2004.01.003 · Cited by 171
Intranasal midazolam vs rectal diazepam in acute childhood seizures
Bhattacharyya, M., Kalra, V., & Gulati, S. (2006) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2005.09.006 · Cited by 152
Fişgin, T., Gurer, Y., Tezic, T., Senbil, N., Zorlu, P., Okuyaz, C., & Akgün, D. (2002) · Journal of Child Neurology · doi:10.1177/088307380201700206 · Cited by 138
Cited by
Kienitz, R., Kay, L., Beuchat, I., Gelhard, S., von Brauchitsch, S., Mann, C., Lucaciu, A., Schäfer, J.-H., Siebenbrodt, K., Zöllner, J.-P., et al. (2022) · CNS Drugs · doi:10.1007/s40263-022-00940-2 · Cited by 139
Benzodiazepines for the Treatment of Seizure Clusters
Penovich, P. E., Rao, V. R., Long, L., Carrazana, E., & Rabinowicz, A. L. (2024) · CNS Drugs · doi:10.1007/s40263-023-01060-1 · Cited by 30
Metadata
- Authors
- Detyniecki, K., Van Ess, P. J., Sequeira, D. J., Wheless, J. W., Meng, T., & Pullman, W. E.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2019-05-29
- Volume
- 60
- Issue
- 9
- Pages
- 1797-1808
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W2947233910
- Cited by
- 105
- References
- 5
- FWCI
- 9.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.